subasumstat,pembrolizumab
merck,takeda
['pembro', 'lcsm,(-blcsm)', 'nsclc', 'sclc', 'subasumstat']
the what s next after pd-l1 immunotx continues. subasumstat (sumoylation blocker) + pembro shows promise in treating mnsclc after progression on pd-l1 inhibitors in ph1b trial. further trials needs to confirm whether this combo is an option #asco22 #lcsm 
LUNGevity Foundation is dedicated to funding lung cancer research and providing support to ALL people affected by lung cancer.